This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-12. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
=== Computing === .MSI, the filename extension of Windows Installer packages Medium scale integration, a generation of integrated circuit chips which contain hundreds of transistors Message Signaled Interrupts, a PCI 2.2 interrupt-mechanism MSI protocol, a basic cache-coherence protocol used in multiprocessor systems
== Clinical significance == Sinus node dysfunction also known as sick sinus syndrome is a group of irregular heartbeat conditions caused by faulty electrical signals of the heart. When the heart's sinoatrial node is defective, the heart's rhythms become abnormal—typically too slow or exhibiting pauses in its function or a combination, and very rarely faster than normal. Blockage of the arterial blood supply to the SA node (most commonly due to a myocardial infarction or progressive coronary artery disease) can therefore cause ischemia and cell death in the SA node. This can disrupt the electrical pacemaker function of the SA node, and can result in sinus node dysfunction. If the SA node does not function or the impulse generated in the SA node is blocked before it travels down the electrical conduction system, a group of cells further down the heart will become its pacemaker.
=== Biomimetic design and photocatalysis === Some MOF materials may resemble enzymes when they combine isolated polynuclear sites, dynamic host–guest responses, and hydrophobic cavity environment which are characteristics of an enzyme. Some well-known examples of cooperative catalysis involving two metal ions in biological systems include: the diiron sites in methane monooxygenase, dicopper in cytochrome c oxidase, and tricopper oxidases which have analogy with polynuclear clusters found in the 0D coordination polymers, such as binuclear Cu2 paddlewheel units found in MOP-1 and [Cu3(btc)2] (btc=benzene-1,3,5-tricarboxylate) in HKUST-1 or trinuclear units such as {Fe3O(CO2)6} in MIL-88, and IRMOP-51. Thus, 0D MOFs have accessible biomimetic catalytic centers. In enzymatic systems, protein units show "molecular recognition", high affinity for specific substrates. It seems that molecular recognition effects are limited in zeolites by the rigid zeolite structure. In contrast, dynamic features and guest-shape response make MOFs more similar to enzymes. Indeed, many hybrid frameworks contain organic parts that can rotate as a result of stimuli, such as light and heat. The porous channels in MOF structures can be used as photocatalysis sites. In photocatalysis, the use of mononuclear complexes is usually limited either because they only undergo single-electron process or from the need for high-energy irradiation. In this case, binuclear systems have a number of attractive features for the development of photocatalysts.
=== Four base (quadruplet) codons === While triplet codons are the basis of the genetic code in nature, programmed +1 frameshift is a natural process that allows the use of a four-nucleotide sequence (quadruplet codon) to encode an amino acid. Recent developments in genetic code engineering also showed that quadruplet codon could be used to encode non-standard amino acids under experimental conditions. This allowed the simultaneous usage of two unnatural amino acids, p-azidophenylalanine (pAzF) and N6-[(2-propynyloxy)carbonyl]lysine (CAK), which cross-link with each other by Huisgen cycloaddition. Quadrupled decoding in wild-type, non-recoded strains is very inefficient. This stems from the fact that the interaction between engineered tRNAs with ternary complexes or other translation components is not as favorable and strong as with cell endogenous translation elements. This problem can be overcome by specifically engineering and evolving tRNA that can decode quadruplet codons in non-recoded strains. Up to 4 different quadruplet orthogonal tRNA/tRNA synthethase pairs can be generated in this manner. Quadruplet codon decoding approach has also been applied to the construction of an HIV-1 vaccine.
He arranged for the bosses of the leading banks and building societies to tour the area in a coach (they were reluctant until Heseltine's PPS Tim Sainsbury persuaded Robin Leigh-Pemberton of NatWest to come), and asked them to each second a bright young manager to the DOE for a year. Heseltine circulated a 21-page minute to Cabinet on his return, entitled It Took a Riot. He proposed a regional office and a review of the status of the Metropolitan Counties, as well as greater government emphasis on Merseyside in future. He had prepared the ground with a small dinner for Whitehall mandarins including Robert Armstrong (Cabinet Secretary) and Ian Bancroft (Head of the Civil Service). However, Thatcher was not impressed, although she agreed to his appointment as Minister for Merseyside for twelve months. Neither was Keith Joseph (Secretary of State for Industry) nor Howe (Chancellor of the Exchequer), who favoured enterprise zones where businesses would be given favourable tax treatment. Shortly after his appointment as Minister for Merseyside, Heseltine gave his annual party conference speech, in which he condemned talk of repatriation and called for more public spending on inner cities. Although he felt he had taken a risk – the speech was in marked contrast to Norman Tebbit's "On Your Bike" speech a few hours later – he received his usual standing ovation and later recorded that it was the one of his speeches of which he was most proud.
Sources: en.wikipedia.org
== N == David Nachmansohn (1899–1983). German biochemist at Columbia, responsible for elucidating the role of phosphocreatine in energy production in muscles. Member Natl. Acad. Sci. USA Joseph Needham FRS (1900–1995). British biochemist at Cambridge, historian and sinologist, noted for embryology and morphogenesis, and also in Chinese science. Eva J. Neer (1937–2000). American physician and biochemist at Harvard, who researched on G-protein cell biology. Member of the National Academy of Medicine. Joe Neilands (1921–2008). Canadian-born American biochemist and political activist at UC Berkeley, known for studies of microbial iron transport, and as author, with Paul K. Stumpf of Outlines of Enzyme Chemistry. Carl Neuberg (1877–1956). German biochemist at the University of Berlin, a pioneer in the study of metabolism. Michael Neuberger (1953–2013). British biochemist and immunologist at Cambridge University known for delineating the role of DNA deamination in immunity. Hans Neurath (1909–2002). American protein chemist at the University of Washington. He was the Founding editor of Biochemistry, which he edited for 30 years (1961–1991). Member Natl. Acad. Sci. USA. Eric Newsholme (1935–2011). British biochemist at the University of Oxford who specialised in human metabolism. Hermann Niemeyer (1918–1991). Chilean biochemist. National Prize of Science (Chile). Member of the Academy of Science of Chile. Marshall Warren Nirenberg (1927–2010).
== External links == Deltamethrin Technical Fact Sheet - National Pesticide Information Center Deltamethrin General Fact sheet - National Pesticide Information Center Pyrethrins and Pyrethroids Fact Sheet - National Pesticide Information Center Deltamethrin Pesticide Information Profile - Extension Toxicology Network Deltamethrin Development Exposure - FASEB Journal
N0 is the initial quantity of the substance that will decay (this quantity may be measured in grams, moles, number of atoms, etc.), N(t) is the quantity that still remains and has not yet decayed after a time t, t½ is the half-life of the decaying quantity, τ is a positive number called the mean lifetime of the decaying quantity, λ is a positive number called the decay constant of the decaying quantity. The three parameters t½, τ, and λ are directly related in the following way:
), as shown by the equations. The distribution coefficient is calculated as the ratio between the concentration of the metal cations in the organic and aqueous phase, whereas the separation factor is calculated as the ratio between the two distribution coefficients.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.